News

US-based biopharmaceutical firm AbbVie has started a global Phase III clinical trial of an investigational oral poly (adenosine diphosphate -ribose) polymerase (PARP) inhibitor 'veliparib (ABT-888)' in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer...

Pleasanton, CA, USA, 21 February 2014 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a licensing agreement with Sysmex Inostics GmbH for its emPCR portfolio of patents. Under the terms of the licensing agreement, Roche grants Sysmex Inostics...

Copenhagen, Denmark, February 21, 2014 - Today announced that it has entered an exclusive license agreement with a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada, for small molecule compounds targeting an...

A Phase IIa clinical study will test the efficacy, safety and tolerability profile Ferrer, a privately-held Spanish pharmaceutical company, today announces that it has executed two agreements; with Ildong Pharmaceuticals Co Ltd, Korea and...

3rd February 2014, India - The Union health ministry of India has turned down some of the state drug controllers' demand for an amendment in Rule 122DAC of the Drugs  & Cosmetics Act to further define the role of...

The Cancer Aid Society of India has urged the government to relax norms with respect to availability and accessibility of oral morphine in the country as thousands of cancer patients are enduring immense pain due to non availability of...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the launch of the SeqCap Epi Target Enrichment System for DNA methylation assessment at single-base resolution. This system includes both a fixed content epigenome-wide design and a full range of custom target...